Hostname: page-component-586b7cd67f-2brh9 Total loading time: 0 Render date: 2024-11-28T14:50:34.446Z Has data issue: false hasContentIssue false
  • English
  • Français

The treatment of atypical depression

Published online by Cambridge University Press:  16 April 2020

DF Klein
DF Klein*
Affiliation:
College of Physicians and Surgeons of Columbian University, Department of Psychiatry, 722 West 168th Street, New York, NY10032, USA
Get access

Summary

Atypical depression differs from typical (endogenomorphic) depression not only in terms of the primary determinant, mood reactivity, but also by the presence of at least one of four atypical symptoms, hyperphagia, hypersomnia, rejection sensitivity and leaden paralysis. In addition to the differential therapeutic response reported by various authors, these two types of depression can be differentiated by various biological measures including the dexamethasone suppression test, tyramine excretion following loading, REM latency, etc. A series of studies comparing phenelzine with imipramine and placebo in subgroups of atypical depressives showed better results with the tricyclic than with placebo; however phenelzine consistently gave the best results in this type of depression. The hypothesis is advanced that the difference between typical and atypical classes of depression could be accounted for by the loss of the ability to experience both “anticipatory” or “consummatory” pleasure in typical depression, but only anticipatory pleasure in atypical depression.

Keywords

typical depressionatypical depressionimipraminephenelzineclinical trialspleasure
Type
Research Article
Information
European Psychiatry , Volume 8 , Issue 5: Worldwide therapeutic strategies in atypical depressive syndromes , 1993 , pp. 251 - 255
Copyright
Copyright © European Psychiatric Association 1993

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Hordern, A (1965) The antidepressant drugs. N Engl J Med 272, 1159–1169CrossRefGoogle ScholarPubMed
Klein, DFDavis, J (1968) Diagnosis and Drug Treatment of Psychiatric Disorders edn 1. Williams and Wilkins, BaltimoreGoogle Scholar
Liebowitz, MRQuitkin, FMStewart, JWMcGrath, PJHarrison, WMMarkowitz, JSRabkin, JGTricamo, EGoetz, DKlein, DF (1988) Antidepressant specificity in atypical depression. Arch Gen Psychiatry 45, 129–138CrossRefGoogle ScholarPubMed
Paykel, ESRowan, PRParker, RRBhat, AV (1982) Response to phenelzine and amitriptyline in sub-types of outpatient depression. Arch Gen Psychiatry 1041–1049CrossRefGoogle Scholar
Quitkin, FMHarrison, WStewart, JWMcGrath, PJTricamo, EOcepek-Welikson, KRabkin, JGWager, SGNunes, EKlein, DF (1991) Response to phenelzine and imipramine in placebo non responders with atypical depression: a new application of the crossover design. Arch Gen Psychiatry 48, 319–323CrossRefGoogle Scholar
Quitkin, FMStewart, JWMcGrath, PJLiebowitz, MRHarrison, WTricamo, EKlein, DFRabkin, JGMarkowitz, JWager, SG (1988) Phenelzine vs imipramine in probable atypical depression: defining syndrome boundaries of selective MAOI responders. Am J Psychiatry 145, 306–312Google Scholar
Ravaris, CLNiss, ARobinson, DSIves, JOLamborn, KRKorson, L (1976) A multiple-dose, controlled study of phenelzine in depression-anxiety states. Arch Gen Psychiatry 33, 347–350CrossRefGoogle ScholarPubMed
Ravaris, DLRobinson, DSIves, JONiss, ABartlett, D (1980) Phenelzine and amitriptyline in the treatment of depression: a comparison of present and past studies. Arch Gen Psychiatry 37, 1075–1080CrossRefGoogle ScholarPubMed
Sargant, W (1960) Some newer drugs in the treatment of depression and their relation to other somatic treatments. Psychosomatics 1, 14–17CrossRefGoogle Scholar
West, EDDally, PJ (1959) Effect of iproniazid in depressive syndromes, Br Med J 1, 1491–1494CrossRefGoogle Scholar
Submit a response

Comments

No Comments have been published for this article.